Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

374791-03-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 374791-03-4 Structure
  • Basic information

    1. Product Name: (R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.)
    2. Synonyms: (R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.);(R)-N-fmoc-4-Fluorophenylglycine(e.e.);(R)-N-FMOC-4-Fluorophenylglycine, 98% ee, 95%;N-Fmoc-R-4-Fluorophenylglycine;Fmoc-D-Phg(4-F)-OH
    3. CAS NO:374791-03-4
    4. Molecular Formula: C23H18FNO4
    5. Molecular Weight: 391.3917232
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 374791-03-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 606.9°Cat760mmHg
    3. Flash Point: 320.8°C
    4. Appearance: /
    5. Density: g/cm3
    6. Vapor Pressure: 1.4E-15mmHg at 25°C
    7. Refractive Index: N/A
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: (R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.)(CAS DataBase Reference)
    11. NIST Chemistry Reference: (R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.)(374791-03-4)
    12. EPA Substance Registry System: (R)-N-FMOC-4-FLUOROPHENYLGLYCINE, 95%, (98% E.E.)(374791-03-4)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: S24/25:Avoid contact with skin and eyes.;
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 374791-03-4(Hazardous Substances Data)

374791-03-4 Usage

Chemical Properties

white crystalline powder

Check Digit Verification of cas no

The CAS Registry Mumber 374791-03-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,4,7,9 and 1 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 374791-03:
(8*3)+(7*7)+(6*4)+(5*7)+(4*9)+(3*1)+(2*0)+(1*3)=174
174 % 10 = 4
So 374791-03-4 is a valid CAS Registry Number.
InChI:InChI=1/C23H18FNO4/c24-15-11-9-14(10-12-15)21(22(26)27)25-23(28)29-13-20-18-7-3-1-5-16(18)17-6-2-4-8-19(17)20/h1-12,20-21H,13H2,(H,25,28)(H,26,27)/p-1/t21-/m1/s1

374791-03-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Fmoc-4-fluoro-D-phenylglycine

1.2 Other means of identification

Product number -
Other names (R)-N-fmoc-4-Fluorophenylglycine(e.e.)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:374791-03-4 SDS

374791-03-4Downstream Products

374791-03-4Relevant articles and documents

PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION

-

Paragraph 0240; 0244; 0245; 0246, (2018/12/13)

The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a, and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction

Karatas, Hacer,Li, Yangbing,Liu, Liu,Ji, Jiao,Lee, Shirley,Chen, Yong,Yang, Jiuling,Huang, Liyue,Bernard, Denzil,Xu, Jing,Townsend, Elizabeth C.,Cao, Fang,Ran, Xu,Li, Xiaoqin,Wen, Bo,Sun, Duxin,Stuckey, Jeanne A,Lei, Ming,Dou, Yali,Wang, Shaomeng

, p. 4818 - 4839 (2017/06/28)

We report herein the design, synthesis, and evaluation of macrocyclic peptidomimetics that bind to WD repeat domain 5 (WDR5) and block the WDR5-mixed lineage leukemia (MLL) protein-protein interaction. Compound 18 (MM-589) binds to WDR5 with an IC50 value of 0.90 nM (Ki value 50 value of 12.7 nM. Compound 18 potently and selectively inhibits cell growth in human leukemia cell lines harboring MLL translocations and is >40 times better than the previously reported compound MM-401. Cocrystal structures of 16 and 18 complexed with WDR5 provide structural basis for their high affinity binding to WDR5. Additionally, we have developed and optimized a new AlphaLISA-based MLL HMT functional assay to facilitate the functional evaluation of these designed compounds. Compound 18 represents the most potent inhibitor of the WDR5-MLL interaction reported to date, and further optimization of 18 may yield a new therapy for acute leukemia.

Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2

Geistlinger, Timothy R.,Guy, R. Kiplin

, p. 6852 - 6853 (2007/10/03)

Nuclear hormone receptor (NR) signaling, currently a therapeutic target in multiple diseases, involves an ordered series of protein interactions to regulate transcription in response to changing hormone levels. Later steps in the process of ligand-dependent signaling are driven by a highly conserved interaction between the NRs and the steroid receptor coactivators (SRCs) that is effected by a conserved interaction motif (L1XXL2L3), known as an NR box. Using computational design and combinatorial chemistry, we have produced novel ∞-helical proteomimetics of the second NR box of SRC2 that exploit structural differences between human estrogen receptor ∞ (hER∞), human estrogen receptor β (hERβ), and human thyroid hormone receptor β (hTRβ). The resulting library sequentially replaced each leucine with non-natural side chains. Screening this library using a quantitative competition assay revealed compounds that selectively inhibit the interaction of SRC2-2 with each individual NR in preference to its interaction with the other NR. This approach generated highly selective compounds from one that had no specificity for a particular family member. These compounds represent the first family-member-selective competitive inhibitors of the protein interactions of transcription factors. Copyright

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 374791-03-4